Lamotrigine induced toxic epidermal necrolysis: A case report. 2020

Kiran Kumar Kc, and Trishant Limbu, and Shirish Shakti Maskay, and Anil Bhasima, and Subhash Prasad Acharya
Department of Critical Care Medicine, Grande International Hospital, Kathmandu, Nepal.

BACKGROUND A wide spectrum of cutaneous adverse reactions ranging from simple maculopapular rashes to more severe and life-threatening reactions like Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis(TEN) have been described after exposure to many antiepileptic drugs. Although the adverse effect following lamotrigine has been reported after a low initial dosage, the risk of developing TEN is relatively rare. METHODS We present a 23-year-old female, 6 months post-partum, a case of complex partial seizure, who developed TEN after 14 days of monotherapy with lamotrigine. She was put on steroids and other supportive management. After a tempestuous course of 9 days in ICU, she made an eventful recovery. CONCLUSIONS Lamotrigine, a chemically different newer antiepileptic, if rapidly titrated and used in conjunction with valproate can cause exfoliative dermatitis-like TEN, but at lower doses and as a monotherapy, female, post-partum, probably due to hormonal factors and strong association between HLA-B*1502 and AED (Antiepileptic drug)-induced SJS/TEN in patients of Asian ethnicity could be other contributing cause. Also, lesser use of lamotrigine in developing nations might have led to a lesser incidence of serious cutaneous adverse reactions. The SCORTEN (Severity-of-illness score for toxic epidermal necrolysis) is the most widely used system to standardize the evaluation of risk and prognosis in patients with TEN. CONCLUSIONS Though rare but TEN can occur following lamotrigine monotherapy. Prompt diagnosis, withdrawal of offending agent, and timely proper supportive care might help in lowering the mortality.

UI MeSH Term Description Entries

Related Publications

Kiran Kumar Kc, and Trishant Limbu, and Shirish Shakti Maskay, and Anil Bhasima, and Subhash Prasad Acharya
June 2003, Acta neurologica Belgica,
Kiran Kumar Kc, and Trishant Limbu, and Shirish Shakti Maskay, and Anil Bhasima, and Subhash Prasad Acharya
June 1997, The Annals of pharmacotherapy,
Kiran Kumar Kc, and Trishant Limbu, and Shirish Shakti Maskay, and Anil Bhasima, and Subhash Prasad Acharya
March 2013, Cutaneous and ocular toxicology,
Kiran Kumar Kc, and Trishant Limbu, and Shirish Shakti Maskay, and Anil Bhasima, and Subhash Prasad Acharya
January 2023, Pakistan journal of medical sciences,
Kiran Kumar Kc, and Trishant Limbu, and Shirish Shakti Maskay, and Anil Bhasima, and Subhash Prasad Acharya
January 1997, Dermatology (Basel, Switzerland),
Kiran Kumar Kc, and Trishant Limbu, and Shirish Shakti Maskay, and Anil Bhasima, and Subhash Prasad Acharya
December 1996, Lancet (London, England),
Kiran Kumar Kc, and Trishant Limbu, and Shirish Shakti Maskay, and Anil Bhasima, and Subhash Prasad Acharya
October 1996, Lancet (London, England),
Kiran Kumar Kc, and Trishant Limbu, and Shirish Shakti Maskay, and Anil Bhasima, and Subhash Prasad Acharya
June 2011, BMJ case reports,
Kiran Kumar Kc, and Trishant Limbu, and Shirish Shakti Maskay, and Anil Bhasima, and Subhash Prasad Acharya
March 1996, Clinical and experimental dermatology,
Kiran Kumar Kc, and Trishant Limbu, and Shirish Shakti Maskay, and Anil Bhasima, and Subhash Prasad Acharya
March 2021, British journal of clinical pharmacology,
Copied contents to your clipboard!